A Good Choice To Have: Scrip’s Interview With Viking CEO Brian Lian

Viking Therapeutics, Inc. sits in a unique but enviable position compared to other clinical-stage companies as it has two candidates in Phase II development that are demonstrating strong therapeutic profiles in a pair of lucrative indications – obesity and metabolic-associated steatohepatitis (MASH).

Seen for years as a potential competitor to Madrigal Pharmaceuticals, Inc. and others in MASH, the San Diego biopharma now is viewed as a potential threat to obesity leaders...